Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So, is this stock still going to $2.5? Just curious.
he's been loading since 0.60. It looks like his boat is overloaded and sinking.
How long until this post is deleted because it is "off-topic".
At least you know that you can only lose 100%.
What makes you think that this will ever go up?
This is fascinating. Seeing this stock keep falling and all these twerps who believe it is still good and trying to pump.
Read the terms of the warrants. As the price goes down, the number of warrants goes up.
For all I care, stay long. Keep losing money. How far are you down so far and how much further down can you afford to go?
I am just trying to help other people from listening to some of the nonsense posted here about how thi sstock is going to shoot to the sky soon.
Texas, if anything there might be a dead cat bounce. Problem is, this dead cat has been falling for a long time and has never hit anything to bounce of of. just look at 6 month chart.
Downtrend, you haven't understood the warrants yet? The owners of the warrants keep getting more shares as the price goes down. They will not stop selling until they have gotten all the 37 million $$ they are owed. As long as somebody is buying they will keep selling. Nothing illegal here, just a bad way of funding the company.
Therefore until all those warrants are dried up this stock will continue to go down, down, down. Time for everyone to understand that. No experiment results or future deals or "40 fun facts" will change that.
And by the way, the company burnt 15 million dollars in the last quarter. If they continue burning cash like that, within 2-3 quarters the company will be worthless.
And you want more bad news? They will face delisting in December if the SP is not above $1. They have stockholder approval for 8:1 reverse split. That is not enough at these prices and if the price will not go up, or they get approval for different reverse split, they are doomed to go to pinkland.
Still believe in AEZS? good luck!
Blue, what happened? You were so upbeat about this stock. Only now you have noticed that it is going down all the time?
The company told us about the warrants a while back and with those warrents there is no way this stock can go up.
Good luck with your complaint. I think alexander talked about filing one long ago. I wonder how that went.
Borg, this will be at $2 before December. I got that from Elvis himself. Yes, he's alive. LOL
Tob, at current price a 12:1 reverse split will get the SP to a dollar.
But... look at what has happened with this stock. Every time good news comes out the sp keeps falling and when there is no news the sp goes down.
Ask yourself a question. On friday at all time low, who sold 13 million shares? And the day before, and the day before and the week before.
Thw warrant holders will keep selling shares, regardless of price until they recievr their $37 million back. Therefore the price will continue to go down sadly enough.
Buying here now is throwing away your money but if you want, go for it. Knock yourself out.
Only a 30:1 split will get them over $1 in order for them to recieve compliance. If they can't do it then hello pinksheets. It's that simple. As of now, nothing has made this stock move up and therefore there is no reason to believe it will start soon no matter what the cheerleaders here on the board are saying.
just look what has happened everytime the company has come out with good news lately (reminder, we are down 80% in the last year).
Lemmy,
Don't confuse everyone with the real facts. It seems as if nobody here has noticed that this stock has been falling for months and no matter what news comes out the price keeps going down.
Everyone here believes that the price will be over 1$ before December. That will happen with a 30:1 reverse split (if they hurry).
Lets see how long this post stays up before it is deleted. Lately everything i post is deleted.
40 Fun Facts - what a joke! When was that originally posted and what heppened since then? It does not make you suspicious or at least skeptic?
The stock is at 8 cents and keeps going lower. Do you really believe it will go up from here?
Reverse split is inevitable or delisting will happen. In the mean time warrant holders keep selling more stock. As long as somebody is buying, they will keep selling and at these prices the estimate is that they have over 100,000,000 stocks to sell.
Don't touch this stock with a ten foot pole!
Stallion, the stock keeps falling and probably half of the 200 million stocks are suckers like me so that leaves 100 million at average price of 15 cents = 15 million $$. They have 37 million$$ to finish their share so at todays prices that means another 220,000,000 shares. That's alot of shares. If I am off by half that still is an impressive amount of shares that can be sold at any price.
You can only lose here unless you are short.
CEO said only 20% of warrants exercised. Need to look at the dollar value since the number goes up as the price goes down. Still alot of downside here.
For B warrant holders this is heaven.
As the stock price declines, they get more and more warrants. All they need to do is sell until the full ammount of their investment is returned to them. Therefore until the B warrants are finished, they will continue to sell and the price will continue to drop.
I wish i had figured that out a few months ago when it was at 30 and instead of buying i would have sold short. Darn!
And by the way, there are C warrants also but I did not go into the details of those.
Such a large volume? Gotta ask yourself who is selling. Someone who bought lower and now is taking profits? That would be logical except we are at alltime lows. I hope very much that i am wrong but this stock seems to be doomed. Everytime some good news comes around that might create some upward momentum, the stock gets hammered. Yesterday included. It has become pitiful.
The stock will go to $2 only after a massive reverse split. I hope I am wrong but lets face the reality.
Where?
Looks like diluters are working real hard to kill this run. 11.5 million shares in 25 minutes. I won't be surprised if within a few days we will hit new lows.
Sighhhhh...
This just keeps on going down. Pennyland? is that where we are going?
In the meantime we're going down, down, down.
Every time we get good news, the SP goes down more. Will today be an exception?
Yeah, right.
When you think it can't get any worse, it does.
Stock report on AEZS from broadstreetalerts.com
Aeterna Zentaris is certainly the Speculator.
Summary:
Aeterna Zentaris is a specialty biopharmaceutical company, engaged in the development and commercialization of novel treatments in oncology, endocrinology, and women's health. The company’s product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development.
Recent News and Analysis
The company recently announced it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. The trial is being conducted in over 120 sites in North America, Europe and Israel. The primary efficacy endpoint is improvement in overall survival. Following its first pre specified interim analysis last April, a Data and Safety Monitoring Board recommended that the ZoptEC Phase 3 study continue as planned. A second interim analysis is expected during Q4, 2015 at approximately 192 events, with the final analysis planned at an anticipated 384 events. The trial is expected to be completed by the end of 2016. In addition to the developments in ZoptEC, the company has three drug candidates in pre-clinical studies, and has moved Macrilen into Phase 3 trials for the evaluation of adult growth hormone deficiency.
Shares of AEZS have retreated dramatically over the past year, falling from a high of $1.54 to as low as $0.20. The drop started when Aeterna Zentaris’ Macrilen drug was not approved by the FDA in Nov 2014. Shares of AEZS have been falling ever since. It is believed the company has reached a bottom and should begin an upward trend. This, of course, is with the assumption that the ZoptEC trials are successful and obtain approval in the future. Chances of this appear higher as it was last reported that the analysis of the drug by the FDA recommended continuing with the next set of trials.
Verdict
AEZS is certainly the speculator in this trio of companies. It is trading at a significant discount to the 52 – week high and certainly has the potential to reach those levels again. However, success rides heavily on the success of the Phase 3 trials for ZoptEC. If unsuccessful in Phase 3 trials, the company does have several more drug candidates which it can continue to develop and hope for a home run.
I guess not.
Can we finally get a good solid green day? God knows we deserve it.
And it is getting more and more undervalued as we speak. At this rate soon we will be paid to buy stocks. Darn!
He recommended AEZS in 2013 when the stock was over 2$. Was he right?
Regardless of whatever this Adam says, we're getting hammered, day after day. I looked at Adam feurstein's track record and it is not very impressive so i don't know what to make of it. If this stock doesn't turn around very soon it will be very sad.
Same story time after time.
We get good news. SP goes way up in pre-market. Market opens, SP starts with an uptrend. After a while in comes some volume and the stock is red.
We see good news, large volume and downward trend. It's driving me sick.
I don't knonothing seems to help this SP. Everytime it starts to look good and then it gets clobbered again. I hope this time it will get up and stay up.
Short squeeze?
5 Stocks Under $10 Set to Soar
Aeterna Zentaris
Another under-$10 specialty biopharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Aeterna Zentaris (AEZS - Get Report), which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. This stock has been smacked lower by the sellers over the last three months, with shares off by 42%.
If you take a look at the chart for Aeterna Zentaris, you'll notice that this stock has been consolidating a bit over the last few weeks, with shares moving between 26 cents on the downside and 33 cents on the upside. Shares of Aeterna Zentaris have started to spike higher right above some near-term support levels at 27 to 26 cents per share. That spike is quickly pushing this stock within range of triggering a near-term breakout trade above some key overhead resistance levels.
Market players should now look for long-biased trades in this stock if it manages to break out above some key near-term overhead resistance levels at 30 to 31 cents per share and then above 32 to 33 cents per share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action 3.12 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at 40 cents to its 50-day moving average of 46 cents, or even 50 to 55 cents per share.
Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at 27 to 26 cents per share. One can also buy shares of Aeterna Zentaris off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
News: Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.
CNW Group
Aeterna Zentaris Inc.
1 hour ago
Aeterna Zentaris and Ascend Therapeutics® to join forces in selling EMD Serono's growth hormone deficiency therapy product
QUÉBEC CITY, May 7, 2015 /CNW Telbec/ - Aeterna Zentaris Inc. (AEZS) (AEZ.TO) and EMD Serono, Inc., the U.S. and Canadian biopharmaceutical businesses of Merck KGaA, Darmstadt, Germany , today announced the finalization of a promotional services agreement that will allow Aeterna Zentaris to promote Saizen® [somatropin (rDNA origin) for injection] to designated medical professionals in specified territories in the United States . Saizen® is a recombinant human Growth Hormone (r-hGH) registered in the U.S. for the treatment of growth hormone deficiency (GHD) in children and adults.
Under the agreement, Aeterna Zentaris will detail Saizen® to designated medical professionals, representing an important incremental field promotion activity in support of the product. Payment to Aeterna Zentaris will be based on new, eligible patient starts on Saizen® above an agreed-upon baseline. Aeterna Zentaris has subcontracted with Ascend Therapeutics® US, LLC, with whom it previously established a co-promotion agreement that is currently underway, to detail Saizen® in territories not covered by Aeterna Zentaris. Financial terms of the agreement were not disclosed.
Jude Dinges , Senior Vice President and Chief Commercial Officer of Aeterna Zentaris, commented on the agreement: "In collaboration with Ascend Therapeutics, our combined 53 sales representatives are eager and poised to begin detailing Saizen®. We recognize the value of direct promotion in this category and we look forward to achieving increased market share and growth for Saizen® by significantly increasing the share-of-voice and impact in support of the product."
David A. Dodd , Chairman and Chief Executive Officer of Aeterna Zentaris stated regarding the promotional services agreement, "This agreement with EMD Serono, a leading US biopharmaceutical company, is another important step toward the transformation of Aeterna Zentaris into a commercially operating company. With its ongoing efforts in the development of electronic recombinant human growth hormone injection devices, EMD Serono is leading innovation in the field of growth hormones, and offers us with Saizen®, a perfect fit for our endocrinology portfolio we are developing and pursuing. We will continue to look for products that we can co-promote or in-license in our core areas of endocrinology and oncology as we build our portfolio and our commercial capabilities."
About Growth Hormone Deficiency (GHD)
Growth hormone deficiency occurs when the pituitary gland in the brain is unable to release or produce adequate amounts of growth hormone. In children, growth hormone deficiency causes slow growth, and without treatment, few will reach their full height potential as an adult.
It is estimated that the incidence of growth hormone deficiency in children is between one in 4,000 and one in 10,000. Non childhood related adult growth hormone deficiency can also be a significant problem which affects three in 10,000 each year. It is recognized as a specific clinical syndrome.
About Saizen® [somatropin (rDNA origin) for injection]
Saizen for Injection is a formulation of a recombinant human growth hormone (GH). In the U.S. Saizen lyophilized product in 5 mg and 8.8 mg strengths is registered for the treatment of appropriate patients with pediatric and adult growth hormone deficiency.
Important Risk Information
Saizen® should not be used in children and adults with a critical illness caused by certain types of heart or stomach surgery, serious injury or a sudden and severe breathing problem, cancer or other tumors, certain types of eye problems caused by diabetes or in children with Prader-Willi syndrome who are severely overweight or have a history of breathing problems including sleep apnea.
The most common side effects reported in clinical trials in children were local reactions at the injection site (such as pain, numbness, redness and swelling), hypothyroidism, low blood sugar, seizures or convulsions, worsening of skin psoriasis, or swelling associated with fluid retention. In adults, pain in joints, muscle pain, tingling and numbness, carpal tunnel syndrome, increased blood sugar or hyperglycemia.
Other possible side effects are return of tumor or cancerous growths, headaches, changes in vision, nausea, vomiting, or pancreatitis. In children, worsening of scoliosis or hip and knee pain.
For full prescribing information, please see www.saizenus.com.
About EMD Serono
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany , is a leading US biopharmaceutical company focused exclusively on specialty care. For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts .
For more information, please visit www.emdserono.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany , is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany , is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States , where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. For more information, visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause Aeterna Zentaris's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of Aeterna Zentaris to efficiently commercialize one or more of its products or product candidates, the ability of Aeterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult Aeterna Zentaris' quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. Aeterna Zentaris does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.
SOURCE Aeterna Zentaris Inc.
up 12.5% AH + a bunch of great anouncements? This is getting very exciting.
Free falling? darn! What happened?
How deep will this pullback be?
Anybody have an idea what this anouncement means?
Sitting on a volcanoe here, about to errupt...
Excellent article.